Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient
Clinical Infectious Diseases2003Vol. 37(2), pp. 311–313
Citations Over TimeTop 10% of 2003 papers
Abstract
Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.
Related Papers
- → Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial(2017)50 cited
- → Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient(2003)79 cited
- → In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies(2004)50 cited
- → In Vitro Activities of Amphotericin B and Voriconazole against Aleurioconidia from Aspergillus terreus(2005)21 cited
- → Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model(2008)5 cited